Our proprietary technology has given rise to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid conjugate that has demonstrated broad-spectrum antiviral activity against the most important dsDNA viruses that affect humans, including adenovirus, the virus that causes smallpox (Variola) and cytomegalovirus (CMV).
Brincidofovir has received Fast Track designation from the U.S. Food and Drug Administration to speed development for the treatment of adenovirus, prevention of CMV, and the treatment of smallpox. Brincidofovir has also received Orphan Medicinal Product Designation from the European Commission for the treatment of adenovirus, the prevention of CMV disease, and for the treatment of smallpox.